[go: up one dir, main page]

NO20081905L - Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander - Google Patents

Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander

Info

Publication number
NO20081905L
NO20081905L NO20081905A NO20081905A NO20081905L NO 20081905 L NO20081905 L NO 20081905L NO 20081905 A NO20081905 A NO 20081905A NO 20081905 A NO20081905 A NO 20081905A NO 20081905 L NO20081905 L NO 20081905L
Authority
NO
Norway
Prior art keywords
histamine
receptor ligands
benzothiazole
cyclobutylamine
derivatives
Prior art date
Application number
NO20081905A
Other languages
English (en)
Inventor
Marlon D Cowart
Minghua Sun
Chen Zhao
Guo Zhu Zheng
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NO20081905L publication Critical patent/NO20081905L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)

Abstract

Forbindelser som oppviser formelen (I) er nyttige i behandlingen av tilstander eller forstyrrelse som kan hindres eller lindres av histamin-3 reseptorligander. Avslørt/fremlagt er også farmasøytiske sammensetninger som består av histamin-3 reseptorligander, metoder for å anvende slike forbindelser og sammensetninger, samt en prosess for å preparere forbindelser som befinner seg innenfor omfanget av formel (I).
NO20081905A 2005-09-22 2008-04-22 Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander NO20081905L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71951605P 2005-09-22 2005-09-22
US11/518,132 US7576110B2 (en) 2005-09-22 2006-09-08 Benzothiazole cyclobutyl amine derivatives
PCT/US2006/036422 WO2007038074A1 (en) 2005-09-22 2006-09-19 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands

Publications (1)

Publication Number Publication Date
NO20081905L true NO20081905L (no) 2008-06-23

Family

ID=37885027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081905A NO20081905L (no) 2005-09-22 2008-04-22 Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander

Country Status (25)

Country Link
US (2) US7576110B2 (no)
EP (2) EP1926729B1 (no)
JP (1) JP2009508957A (no)
KR (1) KR20080050628A (no)
AT (1) ATE538119T1 (no)
AU (1) AU2006295065C1 (no)
BR (1) BRPI0616146A2 (no)
CA (1) CA2623252A1 (no)
CR (1) CR9822A (no)
CY (1) CY1112727T1 (no)
DK (1) DK1926729T3 (no)
EC (1) ECSP088326A (no)
ES (1) ES2378197T3 (no)
HR (2) HRP20120251T1 (no)
IL (1) IL190350A (no)
MY (2) MY146028A (no)
NO (1) NO20081905L (no)
NZ (1) NZ566834A (no)
PL (1) PL1926729T3 (no)
PT (1) PT1926729E (no)
RS (1) RS52231B (no)
SI (1) SI1926729T1 (no)
TW (1) TWI393717B (no)
WO (1) WO2007038074A1 (no)
ZA (1) ZA200802508B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576110B2 (en) * 2005-09-22 2009-08-18 Abbott Laboratories Benzothiazole cyclobutyl amine derivatives
TW200808773A (en) * 2006-06-23 2008-02-16 Abbott Lab Cyclopropyl amine derivatives
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AU2008240832A1 (en) * 2007-04-19 2008-10-30 Ucb Pharma S.A. Histamine H3 receptor ligands comprising a cyclobutoxy group
US8153813B2 (en) * 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
CN101925606A (zh) * 2008-01-24 2010-12-22 Ucb医药有限公司 包含环丁氧基的化合物
KR100986433B1 (ko) 2008-05-30 2010-10-08 현대자동차주식회사 전동식 파워스티어링 시스템
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
EP3010889B1 (de) 2013-06-20 2018-10-03 Bayer CropScience Aktiengesellschaft Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
BR112019025740A2 (pt) 2017-06-05 2020-06-23 Ptc Therapeutics, Inc. Compostos para tratar a doença de huntington
EP3774744B1 (en) 2018-03-27 2025-02-12 PTC Therapeutics, Inc. Compounds for treating huntington's disease
SG11202012869SA (en) 2018-06-27 2021-01-28 Ptc Therapeutics Inc Heteroaryl compounds for treating huntington's disease
WO2021222366A1 (en) * 2020-04-28 2021-11-04 Kymera Therapeutics, Inc. Irak inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US78133A (en) * 1868-05-19 Improvement in heuometebs
US224952A (en) * 1880-02-24 Nventor
US171181A (en) * 1875-12-14 Improvement in fence-posts
DE491224C (de) 1923-05-20 1930-02-22 Leopold Cassella & Co G M B H Verfahren zur Darstellung von Arylaminosubstitutionsprodukten von o-Aminoarylmercaptanen
GB8621790D0 (en) 1986-09-10 1986-10-15 Ici Plc Tertiary amine compounds
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
RU2174505C1 (ru) 2000-02-18 2001-10-10 Открытое акционерное общество "Всероссийский научно-исследовательский институт органического синтеза" Способ получения функционально замещенного метиленциклобутана
DE10155202A1 (de) * 2001-11-09 2003-07-31 Boehringer Ingelheim Int Herstellung und Verwendung von substituierten Imidazolen
US20030131975A1 (en) * 2002-01-11 2003-07-17 Sabina Houle Integrated heat spreader with mechanical interlock designs
CA2505427C (en) 2002-11-12 2012-04-03 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
JP2007519707A (ja) * 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク ヒスタミン−３受容体モジュレーター
MX2007015165A (es) 2005-06-03 2008-02-14 Abbott Lab Derivados de ciclobutil-amina.
US7576110B2 (en) * 2005-09-22 2009-08-18 Abbott Laboratories Benzothiazole cyclobutyl amine derivatives

Also Published As

Publication number Publication date
TWI393717B (zh) 2013-04-21
HRP20120251T1 (hr) 2012-07-31
EP1926729A1 (en) 2008-06-04
CY1112727T1 (el) 2016-02-10
IL190350A0 (en) 2009-09-22
US7576110B2 (en) 2009-08-18
RU2008115313A (ru) 2009-10-27
DK1926729T3 (da) 2012-03-19
WO2007038074A1 (en) 2007-04-05
ZA200802508B (en) 2012-09-26
CR9822A (es) 2008-08-01
PL1926729T3 (pl) 2012-05-31
ES2378197T3 (es) 2012-04-09
HRP20080174A2 (hr) 2008-12-31
MY146028A (en) 2012-06-15
EP1926729B1 (en) 2011-12-21
HK1118291A1 (en) 2009-02-06
EP2386556B1 (en) 2013-10-23
MY150990A (en) 2014-03-31
AU2006295065C1 (en) 2012-11-22
BRPI0616146A2 (pt) 2011-06-07
US20090326222A1 (en) 2009-12-31
US20070066588A1 (en) 2007-03-22
ATE538119T1 (de) 2012-01-15
ECSP088326A (es) 2008-04-28
AU2006295065A1 (en) 2007-04-05
SI1926729T1 (sl) 2012-04-30
NZ566834A (en) 2011-08-26
PT1926729E (pt) 2012-03-27
KR20080050628A (ko) 2008-06-09
RS52231B (sr) 2012-10-31
CA2623252A1 (en) 2007-04-05
JP2009508957A (ja) 2009-03-05
AU2006295065B2 (en) 2012-03-08
US8592467B2 (en) 2013-11-26
EP2386556A1 (en) 2011-11-16
TW200745098A (en) 2007-12-16
IL190350A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
ATE530519T1 (de) Cyclobutylaminderivate
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
CY1112237T1 (el) Παραγωγα 5-υδροξυ-βενζοθειαζολης που εχουν ενεργοτητα αγωνιστη βητα-2-αδρενοϋποδοχεα
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20081217L (no) Nye benzotiazolonderivater
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20053748L (no) Pyrrolopyridazinderivater.
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20090282L (no) Syklopropylaminderivater som histamin H3 reseptormodulatorer
DK1989174T3 (da) Substituerede cyclohexylmethyl-derivater
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
NO20082589L (no) Nye indolizinderivater, fremgangsmate for fremstilling av samme og terapeutiske sammensetninger som inbefatter samme
UA94242C2 (ru) Производные бензотиазолциклобутиламина и их применение как лигандов рецепторов гистамина-3
ATE412416T1 (de) Indolin-2-one-pyridin-derivate, herstellung und therapeutische verwendung dafür

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE INC., US

FC2A Withdrawal, rejection or dismissal of laid open patent application